Click to enlarge

TZ 2G

Name: TZ 2G
SKU: RPP-PRP-003
Price: 79.90 EUR
Availability: InStock

79,90 € Vial

5% off when paying with cryptocurrency

incl. VAT plus Shipping Costs

Synthetic 39-amino acid peptide characterized as a dual agonist at the GLP-1 and GIP receptors ("twincretin"), supplied as a tool compound for incretin pathway research.
Structural modifications include Aib² and Aib¹³ for reduced DPP-4 susceptibility, and a C20 fatty diacid at Lys²⁰ mediating reversible albumin binding.
Purity ≥99% (HPLC-verified), documented per batch in a lot-specific Certificate of Analysis.
Supplied as lyophilized powder, 10 mg per vial.
Research applications: incretin receptor pharmacology, cAMP signal transduction, comparative agonism studies, analytical method development.
Store at −20 °C. For research use only. Not for human or veterinary use.

Quantity	Price	Discount
11-20	67,91 € Vial	15%
21+	63,92 € Vial	20%

Delivery time: 1–6 Working Days

Add 70,00 € to cart and get free shipping!

Buy now

Compare

Add to wishlist

SKU: RPP-PRP-003 Categories: Energy, Longevity, Metabolism, Research peptides Tags: Beta Cell Research, Dual Agonist, GIP, GLP-1, Glucose Metabolism, Incretin Mimetic, Insulin Secretion, Metabolic Research, Twincretin

Description

RESEARCH USE ONLY. For laboratory research use only. Not a drug, food, cosmetic, or medical device. Not for human or veterinary use, diagnostic use, or any form of administration. Handling restricted to qualified personnel in a controlled laboratory environment.

Key Specifications

Parameter	Specification
Type	Synthetic dual incretin mimetic (twincretin)
Target Receptors	GLP-1R + GIPR
Sequence Length	39 amino acids
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight	4,813.45 Da
CAS Number	2023788-19-2
Key Modifications	Aib², Aib¹³, Lys²⁰-C20 fatty diacid, C-terminal amide
Form	Lyophilized powder
Appearance	White to off-white lyophilized powder
Purity	≥99% (HPLC), per batch-specific Certificate of Analysis
Quantity	10 mg
Storage	−20 °C

Product Overview

TZ Peptide is a synthetic 39-amino acid peptide characterized as a dual agonist at the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This dual-receptor profile — described in the literature as a "twincretin" — combines the binding determinants of two incretin systems in a single sequence.

The peptide carries three structural modifications relevant to its physicochemical behaviour: α-aminoisobutyric acid (Aib) at positions 2 and 13, which sterically hinders DPP-4 cleavage; a C20 fatty diacid conjugated at lysine-20 via a hydrophilic linker, which mediates reversible albumin binding; and C-terminal amidation.

Biochemical Profile

Property	Value
Sequence	Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(γ-Glu-AEEA-AEEA-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
C-Terminus	Amidated (–NH₂)

Structural Modifications

Aib² and Aib¹³ — non-coded residues whose quaternary α-carbon introduces steric hindrance at the DPP-4 recognition site, reducing susceptibility to enzymatic cleavage.
Lys²⁰-C20 fatty diacid — eicosanedioic acid attached through a γ-Glu-(AEEA)₂ hydrophilic linker, conferring reversible albumin binding. Extended plasma residence associated with this modification is described in published pharmacokinetic literature.
C-terminal amidation — the C-terminus is present as the carboxamide rather than the free acid.

Receptor Pharmacology

The following summarizes established incretin receptor biology as reported in the scientific literature. It describes the receptor systems this reagent is used to investigate.

GLP-1R and GIPR are class B G-protein-coupled receptors. Agonist binding promotes Gs coupling, adenylyl cyclase activation and intracellular cAMP accumulation, followed by PKA-mediated phosphorylation events. In pancreatic beta-cell models this signalling axis is associated with glucose-dependent modulation of insulin secretion.

Compounds engaging both receptors are described in the literature as dual incretin agonists. Comparative characterization of dual versus single-receptor engagement at the assay level is an active area of published in vitro research.

Research Applications

Supplied as a reference standard and tool compound for in vitro and preclinical investigation.

Incretin Receptor Pharmacology — binding affinity determination, cAMP accumulation assays, β-arrestin recruitment, receptor internalization kinetics.
Signal Transduction — Gs/cAMP/PKA pathway characterization in transfected cell lines and primary islet preparations.
Comparative Agonism — dual- versus single-receptor engagement as a methodological comparator.
Structure–Activity Studies — contribution of Aib substitution and lipidation to protease resistance and albumin binding in vitro.
Peptide Chemistry and Analytics — reference material for HPLC and MS method development, stability and degradation studies.

All applications are limited to controlled laboratory research environments.

Analytical Verification

Each batch is released against a lot-specific Certificate of Analysis documenting:

RP-HPLC — purity determination by optimized gradient separation
ESI-MS — molecular weight confirmation and verification of Aib residues and C20 diacid conjugation
Amino acid analysis — composition verification
Peptide content quantification
Residual solvent screening

Stability

Condition	Data
Lyophilized, −20 °C	Stable for 24 months
Reconstituted solutions	Reduced stability; store frozen in single-use aliquots
Light exposure	Protect from light
Freeze–thaw	Avoid repeated cycles

Regulatory Status

TZ Peptide is supplied exclusively as a research reagent for laboratory use and is not placed on the market for therapeutic, diagnostic or consumer applications.

Frequently Encountered Inquiries

How does TZ Peptide differ from single-target incretin mimetics?
TZ Peptide engages both GLP-1R and GIPR, whereas single-target compounds engage GLP-1R alone. This makes it useful as a comparator in receptor-level studies of dual versus single-receptor engagement.

What are the key structural modifications?
Aib residues at positions 2 and 13 hinder DPP-4 cleavage. Lysine-20 carries a C20 fatty diacid (eicosanedioic acid) through a γ-Glu-(AEEA)₂ hydrophilic linker, mediating albumin binding. The C-terminus is amidated.

What research applications are appropriate?
Incretin receptor pharmacology, signal transduction characterization, structure–activity studies, and analytical method development. All applications limited to controlled laboratory environments.

What are the storage requirements?
Lyophilized material is stable for 24 months at −20 °C. Reconstituted solutions show reduced stability and should be aliquoted and frozen. Protect from light and avoid repeated freeze–thaw cycles.

Is a Certificate of Analysis provided?
Yes. Each batch ships with a lot-specific CoA documenting HPLC purity, MS identity confirmation and peptide content.

Additional information

Dosage	10mg, 20mg, 40mg, 50mg, 5mg

Product safety

Safety instructions

SAFETY DATA SHEET (SDS)

TZ Peptide — Research-Grade Lyophilized Powder (RUO)

CAS Number: 2023788-19-2
Synonyms: GLP-1/GIP dual receptor agonist, twincretin
REACH: Not subject to registration at quantities below 1 tonne per year (scientific research and development)

SECTION 1 — Identification

1.1 Product Identifier: TZ Peptide — Lyophilized Powder
CAS 2023788-19-2 · EC number: not assigned · Index number: not assigned

1.2 Identified Uses: Analytical-grade peptide for in-vitro laboratory research. Research Use Only (RUO).
Uses advised against: Human or veterinary use, administration in any form, diagnostic use, food, cosmetic or consumer applications.

1.3 Supplier:
BIONIX RESEARCH — [legal entity]
[full postal address — required]
[telephone number — required]
info@bionixresearch.com

1.4 Emergency Telephone: [24 h emergency / national poison centre — required]
General emergency (EU): 112

SECTION 2 — Hazards Identification

2.1 Classification: Based on available data, the classification criteria of Regulation (EC) No 1272/2008 (CLP) are not met. No GHS pictograms, signal word or hazard statements required.

2.2 Label elements: None required under CLP.

2.3 Other hazards:

Pharmacologically active compound — handle with appropriate care
Avoid dust formation and inhalation
Avoid contact with eyes and skin
Laboratory use only
Not assessed as PBT or vPvB (no data available)

SECTION 3 — Composition / Information on Ingredients

Substance (not a mixture).

Property	Value
Substance	TZ Peptide
CAS	2023788-19-2
EC number	Not assigned
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight	4,813.45 Da
Purity	≥99% (HPLC)
Form	Lyophilized powder
Structure	39-amino acid peptide with Aib², Aib¹³ and C20 fatty diacid at Lys²⁰
Impurities	None present at concentrations requiring classification

SECTION 4 — First-Aid Measures

Inhalation: Move to fresh air. Rinse mouth and nose. Seek medical attention if symptoms persist.

Skin Contact: Remove contaminated clothing. Wash affected area thoroughly with soap and water. Seek medical attention if irritation develops or persists.

Eye Contact: Rinse cautiously with clean water for at least 15 minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention if irritation persists.

Ingestion: Rinse mouth thoroughly. Do not induce vomiting. Seek medical advice immediately due to pharmacological activity.

Most important symptoms: Accidental systemic exposure may produce pharmacological effects, including hypoglycaemia, nausea and gastrointestinal disturbance.

Notes to Physician: This substance is a pharmacologically active GLP-1/GIP receptor agonist. Treat symptomatically. Monitor blood glucose following significant exposure. No specific antidote available.

SECTION 11 — Toxicological Information

Acute Toxicity: No toxicological data available for this material. Low acute toxicity anticipated based on peptide nature.

Routes of Exposure:

Inhalation: Dust may cause respiratory tract irritation
Skin: May cause mild irritation; systemic absorption of a pharmacologically active compound cannot be excluded
Eyes: May cause irritation
Ingestion: May cause gastrointestinal effects; pharmacological activity possible

Pharmacological Activity: This substance is a potent GLP-1/GIP receptor agonist. Incretin receptor activation is associated in the literature with glucose-dependent modulation of insulin secretion, glucagon release and gastric motility. Accidental exposure may therefore result in pharmacological effects, including hypoglycaemia, nausea or gastrointestinal disturbance.

Chronic Toxicity: No data available.
Carcinogenicity: No data available for this substance. Not listed by IARC, NTP or OSHA.
Germ Cell Mutagenicity: No data available.
Reproductive Toxicity: No data available.
STOT (single / repeated exposure): No data available.
Aspiration Hazard: Not applicable.

SECTION 5 — Fire-Fighting Measures

Extinguishing Media: CO₂, dry chemical, foam, or water spray.
Unsuitable Media: None known.
Specific Hazards: Organic peptide powder; non-flammable under normal conditions. Thermal decomposition may release carbon monoxide, carbon dioxide and nitrogen oxides.
Firefighter Protection: Self-contained breathing apparatus and full protective clothing.

SECTION 6 — Accidental Release Measures

Personal Precautions: Avoid dust formation. Wear appropriate PPE including gloves, respiratory protection and eye protection. Ensure adequate ventilation.
Environmental Precautions: Prevent release into drains, waterways or soil.
Containment / Cleanup: Collect powder carefully using appropriate tools, avoiding dust generation. Transfer to a sealed, labelled waste container. Clean contaminated surfaces with water.

SECTION 7 — Handling and Storage

Handling:

Use only in laboratory settings with appropriate engineering controls
Minimize dust formation
Wear standard PPE (gloves, lab coat, eye protection)
Avoid inhalation, ingestion and skin contact
Handle powder in a fume hood or well-ventilated area
Wash hands thoroughly after handling

Storage:

Store at −20 °C in the original sealed vial
Protect from light, heat and humidity
Keep container tightly closed
Store away from oxidizing agents
Research use only

Reconstituted solutions: Reduced stability compared with lyophilized material. Store refrigerated (2–8 °C) for short-term handling, or aliquot and store frozen. Protect from light. Avoid repeated freeze–thaw cycles.

SECTION 8 — Exposure Controls / Personal Protection

Exposure Limits: No occupational exposure limits established.
Engineering Controls: Local exhaust ventilation or fume hood when handling powder.

Protection	Recommendation
Hands	Nitrile gloves (double gloving recommended)
Eyes	Safety glasses or goggles to EN 166
Skin	Lab coat, long sleeves
Respiratory	FFP2/N95 or higher when handling powder

Hygiene Measures: Wash hands thoroughly after handling. Do not eat, drink or smoke in the work area.

SECTION 9 — Physical and Chemical Properties

Property	Value
Appearance	White to off-white lyophilized powder
Odour	None
Odour threshold	Not determined
Melting point	Not determined (decomposes before melting)
Boiling point	Not applicable
Flash point	Not applicable
Evaporation rate	Not applicable
Flammability	Not classified as flammable
Vapour pressure / density	Not applicable
Relative density	Not determined
Solubility	Soluble in aqueous buffers
Partition coefficient (log P_ow)	Not determined
Auto-ignition temperature	Not determined
Decomposition temperature	Not determined
Viscosity	Not applicable
Explosive / oxidising properties	None expected
Stability	Stable at −20 °C; sensitive to heat and moisture

SECTION 10 — Stability and Reactivity

Reactivity: No hazardous reactions under normal conditions of use.
Chemical Stability: Stable under recommended storage conditions (−20 °C, sealed, protected from light).
Conditions to Avoid: Heat, moisture, air exposure, repeated freeze–thaw cycles, prolonged light exposure.
Incompatible Materials: Strong oxidizing agents, strong acids, strong bases.
Hazardous Decomposition Products: Carbon monoxide, carbon dioxide, nitrogen oxides.

SECTION 12 — Ecological Information

Ecotoxicity: No data available. Significant environmental risk not expected at research quantities.
Persistence / Degradability: Expected to be biodegradable as a peptide. No test data available.
Bioaccumulative Potential: Not expected to bioaccumulate.
Mobility in Soil: Water soluble; may be mobile in soil.
PBT / vPvB Assessment: Not performed; no data available.
Other Adverse Effects: Prevent release into water systems, drains or soil.

SECTION 13 — Disposal Considerations

Disposal Method: Dispose in accordance with local, regional and national regulations for laboratory chemical waste and pharmacologically active compounds.
Contaminated Packaging: Dispose as chemical waste. Do not reuse containers.
Special Precautions: Do not dispose via household waste or sewer systems. Incineration at a licensed facility is recommended.

SECTION 14 — Transport Information

Regulation	Classification
ADR (Road)	Not regulated
IMDG (Sea)	Not regulated
IATA (Air)	Not regulated
UN Number	Not assigned
Proper Shipping Name	Not applicable
Hazard Class	Not applicable
Packing Group	Not applicable
Environmental hazards	Not classified as marine pollutant

Special Precautions: Ship in an insulated container with cold packs. Label as "Research Use Only — Not for Human Use".

SECTION 15 — Regulatory Information

EU Regulations:

Not subject to registration under REACH (EC) No 1907/2006 at quantities below 1 tonne per year
Based on available data, does not meet the classification criteria of CLP Regulation (EC) No 1272/2008
Not authorised as a medicinal product in the EU. Supplied exclusively as a research reagent and not placed on the market for therapeutic use.

Other Regulations:

Not a controlled substance
Not listed under the Rotterdam Convention
Not listed under the Stockholm Convention

Chemical Safety Assessment: Not performed.

Product Status: Research Use Only. Not approved for human or veterinary therapeutic, diagnostic or cosmetic applications.

SECTION 16 — Other Information

Revision Date: [insert date]
Version: 1.1 — supersedes version 1.0

Abbreviations: CLP — Classification, Labelling and Packaging · GHS — Globally Harmonized System · PPE — Personal Protective Equipment · RUO — Research Use Only · HPLC — High-Performance Liquid Chromatography · Aib — α-Aminoisobutyric acid · PBT — Persistent, Bioaccumulative, Toxic · vPvB — very Persistent, very Bioaccumulative · STOT — Specific Target Organ Toxicity

References: CLP Regulation (EC) No 1272/2008 · REACH Regulation (EC) No 1907/2006

Disclaimer: This Safety Data Sheet is intended for trained laboratory personnel handling research-grade materials. The information is based on current knowledge at the date of issue. It does not signify suitability for therapeutic, diagnostic or consumer applications. Users must make their own assessment of the material's suitability for their specific purposes.

BIONIX RESEARCH — info@bionixresearch.com
For Research Use Only. Not for human or veterinary use.

Storage

STORAGE AND HANDLING

Lyophilized Peptide Stability

All BIONIX Research products are manufactured using lyophilization — a pharmaceutical-industry freeze-drying process that creates a stable crystalline structure, removing approximately 95% of moisture from the peptide compound.

This technology ensures up to 3-4 months of stability at ambient temperatures during shipping and storage. The result: a pure, puffy white powder that maintains structural integrity until reconstitution, regardless of logistical conditions.

Condition	Duration
-20°C	Up to 24 months
2-8°C	Up to 3 months (short-term)

Protect from light and moisture. The lyophilized state prevents hydrolytic degradation and maintains peptide bond integrity.

Reconstitution Protocol:

Solvent: Sterile bacteriostatic water or appropriate buffer
Technique: Add solvent slowly along vial wall
Mixing: Gently swirl until dissolved—do not shake or vortex (shear forces damage peptide bonds)
Sterility: Maintain aseptic conditions throughout

Post-Reconstitution Storage:

2-8°C: Use within 4 weeks
Aliquot and freeze at -20°C for extended storage
Avoid repeated freeze-thaw cycles
Protect from light and moisture

The 3-Tier Storage Protocol

STABLE - Prewritten Phase (Up to 4 Months) Unreconstituted lyophilized peptides remain chemically stable at room temperature (15-25°C) for 3-4 months when stored away from direct sunlight and moisture. The sealed vacuum packaging provides oxidative protection during this window.

FRESH - Active Phase (Up to 30 Days) Once reconstituted with bacteriostatic water, immediate refrigeration at 2-8°C is required. Stability degrades rapidly above this threshold — refrigerate within 30 minutes of reconstitution for optimal preservation.

PRESERVATION - Long-Term Phase (6-12 Months+) For extended storage beyond 30 days, transfer to -20°C (standard freezer, not frost-free). At this temperature, most reconstituted peptides maintain stability for 6-12 months. Note: Avoid freeze-thaw cycles — each temperature fluctuation degrades peptide bonds.

Quality Indicators to Monitor

Visual inspection: Solution should remain clear; cloudiness indicates degradation
Precipitation: Particulates signal protein denaturation — discard immediately
Temperature logs: Use a calibrated thermometer; refrigerator door storage fluctuates more than back shelves
Time tracking: Label each vial with reconstitution date — 30-day countdown begins at mixing

Handling Best Practices

Store peptides in their original amber vials until reconstitution. Post-reconstitution: dark glass, light-blocking storage containers recommended. Never expose vials to direct sunlight or UV light — photodegradation occurs within hours.

For detailed Complete Peptide Storage Protocol access our Guide. Complete Peptide Storage Protocol

Legal Notice

This product is intended exclusively for laboratory research. Not approved for human use, not for therapeutic applications, and not for in vivo studies in humans.

The buyer confirms that this product will be used exclusively for research purposes in an appropriate laboratory environment.